News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SetPoint Medical Presents Positive Clinical Results for First Human Study of Implantable Neuromodulation Device for Rheumatoid Arthritis


11/12/2012 10:15:20 AM

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a biomedical technology company developing neuromodulation therapies for inflammatory diseases, presented positive results from a first-in-human study using a neuromodulation device to treat rheumatoid arthritis (RA) yesterday at the American College of Rheumatology annual meeting in Washington, D.C. “In contrast to immunosuppressive drugs, the neuromodulation therapy in this study used an implantable pulse generator to stimulate the vagus nerve, activating the body’s natural Inflammatory Reflex to produce a systemic anti-inflammatory effect,” said Dr. Kevin Tracey, President of Feinstein Institute for Medical Research, discoverer of the inflammatory reflex, and co-author of the ACR presentation. “The results of this study show promising clinical efficacy, and confirm a decade of foundational scientific research done by our laboratory and others.”

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES